A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Conditions
Recurrent Ovarian Cancer
What is the purpose of this trial?
AMG 386 is a first-in-class investigational anti-angiogenic drug that provides potent and
selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. AMG 386 is engineered by fusing truncated human IgG1 Fc domain to 4 copies of a synthetic anti-angiopoietin peptide. The resultant molecule is a nonglycosylated protein, and its biologically active form is a covalently linked homodimer.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Female
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Amgen, Inc
- Dates:
- November 2011
- Last Updated:
- Study HIC#:
- 1009007411
Clinicaltrials.gov ID: Yale3202892
